February issue reader poll
Gestational diabetes: Should you use oral agents?
Most relevant: 77%
Somewhat relevant: 3%
Least relevant: 20%
Examining the evidence on vitamin D, calcium, and CVD risk
Most relevant: 14%
Somewhat relevant: 75%
Least relevant: 11%
Oral contraceptives: What you need to know about the latest formulations
Most relevant: 55%
Somewhat relevant: 33%
Least relevant: 12%
Clinical Insights:
Infection resistance dips during ovulation
Most relevant: 11%
Somewhat relevant: 58%
Least relevant:31%
Twins from IVF help each other survive in utero
Most relevant: 31%
Somewhat relevant: 39%
Least relevant: 30%
US obesity rates: astronomical but leveling
Most relevant: 31%
Somewhat relevant: 39%
Least relevant: 30%
Moderately preterm infants have more emotional issues
Most relevant: 50%
Somewhat relevant: 47%
Least relevant: 3%
Smartphones may increase risk of health data breaches
Most relevant: 20%
Somewhat relevant: 69%
Least relevant: 11%
HHS overrules expanded availability of Plan B
Most relevant: 33%
Somewhat relevant: 47%
Least relevant: 20%
Legally Speaking: Lack of informed consent alleged after elective induction of labor
Most relevant: 67%
Somewhat relevant: 25%
Least relevant: 8%
SMFM Consult: Pregnancy in women with spinal cord injuries
Most relevant: 22%
Somewhat relevant: 55%
Least relevant: 23%
Meeting Coverage: ASRM takes on fertility knowledge gap, ‘personhood’ legislation
Most relevant: 19%
Somewhat relevant: 58%
Least relevant: 23%
FDA grants 510(k) clearance to chemiluminescence-based immunoassay
Published: January 10th 2025 | Updated: January 10th 2025The automated chemiluminescence-based immunoassay has received clearance for free testosterone, providing enhanced diagnostic options to a multitude of conditions.
Read More